<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320372</url>
  </required_header>
  <id_info>
    <org_study_id>TRD Registry</org_study_id>
    <nct_id>NCT00320372</nct_id>
    <nct_alias>NCT00657215</nct_alias>
  </id_info>
  <brief_title>Treatment-Resistant Depression Registry</brief_title>
  <official_title>A Long-term, Prospective, Observational, Multi-center Patient Outcome Registry to Collect Data in Patients With Treatment-resistant Depression (TRD) Who Are Currently in a Major Depressive Episode.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will collect information about patients with treatment-resistant depression
      (TRD) who are currently in a major depressive episode. For the purposes of this study, TRD is
      defined as an ongoing depression lasting at least 2 years or that has recurred at least 3
      times, to include the current episode, during the patient's lifetime AND has not adequately
      responded to 4 or more adequate antidepressive treatments. The registry will follow the
      clinical course and outcomes for patients with TRD who are treated with and without
      adjunctive (used along with other treatments for depression) vagus nerve stimulation (VNS)
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment of TRD patients treated with VNS Therapy will consist of patients originally
      enrolled in the registry as well as patients who have completed the D-21 Dosing Study and are
      enrolled in the Registry for Long-Term Follow-up. Sites will maintain a screening log of all
      patients who have been screened for original TRD Registry patients.

      Please note that because this is a post-approval registry, Cyberonics does not cover the cost
      of VNS Therapy implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)% Responders (&gt;/= 50% Improvement From Baseline)</measure>
    <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
    <description>Response Rate was computed and summarized as the proportion of patients that achieved ≥ 50% reduction from baseline in MADRS total score at each post-baseline visit. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen. A patient was considered a &quot;Responder&quot; (Yes = 1) if achieved ≥ 50% reduction from baseline in MADRS total score at visit month assessment post-baseline. A &quot;Non-Responder&quot; (No = 0) was any patient who did not achieve ≥ 50% reduction from baseline in MADRS score at visit month assessment post-baseline.
Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Until Recurrence (TUR) for Patients That Achieved Remission, Based on Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
    <description>Recurrence based on MADRS is defined as first time attained MADRS total score ≥ 20 after achieving remission. Remission is a binary outcome response variable (Yes/No in-remission) defined as MADRS total score &lt;/= 9 at visit month assessment post-baseline. Duration of remission Computed as recorded date of the first recurrence/relapse (MADRS score &gt;/= 20) minus the recorded date of first achieved remission (MADRS score &lt;/=9). Only a subpopulation that achieved remission will be included in the summary.
Time-to-event analyses were summarized using Kaplan-Meier curves. Patients who did not achieve recurrence at the end of the study were censored on the last visit date recorded. Additionally, patients who discontinued early were censored on last date of contact. Censored observations and confidence intervals for the estimated median times were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)% Remitters (MADRS Total Score ≤9 at Visit Month Assessment Post-Baseline)</measure>
    <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
    <description>Remission is a binary outcome response variable (Yes/No Inremission) defined as MADRS total score &lt; 9 at visit month assessment post-baseline. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen and in general it is accepted that a score between 0-6 is indicative of a normal/symptom-free individual; 7-19 is indicative of a patient with mild depression; 20-34 is indicative of a patient with moderate depression; and &gt;34 is indicative of a patient with severe depression. Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Baseline MADRS Item 10 Suicidal Ideation</measure>
    <time_frame>1 Week Pre-Baseline</time_frame>
    <description>This assessment was completed telephonically by a third party rater (Central Rater Group). The rating was based on a clinical interview moving from broadly phrased questions about symptoms to more detailed ones, which allowed a precise rating of severity. The rater decided whether the rating lied on the defined scale steps (0, 2, 4, 6) or between them (1, 3, 5) and then checked the appropriate selection on the MADRS Item 10 Suicidal Thoughts (Ideation).
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Medical Threat to Life of Most Recent Suicidal Gesture</measure>
    <time_frame>Baseline</time_frame>
    <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's medical threat to life of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Intent of Most Recent Suicidal Gesture</measure>
    <time_frame>Baseline</time_frame>
    <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's intent of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Primary Diagnosis of MDE</measure>
    <time_frame>Screening</time_frame>
    <description>This assessment was completed by the physician at the screening visit. The physician decided which DSM-IV Diagnosis (as shown in outcome measure data table) best characterized the patient's primary diagnosis of MDE.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">795</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1. 500 VNS Patients</arm_group_label>
    <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. 300 Non-VNS Patients</arm_group_label>
    <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic depression that is at least two years in duration or a recurrent
        depression that includes at least three lifetime episodes including the current major
        depressive episode (MDE); and an inadequate response to four or more adequate
        antidepressant treatments.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with a current major depressive episode according to DSM-IV-TR
             criteria.

          -  For D-21 patients only who have completed the D-21 dosing Study without any D-21
             inclusion and exclusion protocol deviation.

          -  Patient has been in the current depressive episode for 2 years or longer, or has had
             at least 3 lifetime episodes including the current MDE.

          -  Patient has had an inadequate response to 4 or more adequate antidepressive
             treatments.

          -  The patient has a CGI severity of illness score of moderately ill (score of 4) or
             greater.

          -  The patient must be able to provide informed consent and complete all forms.

        Exclusion Criteria:

          -  Patient has a history of schizophrenia, schizoaffective disorder, any other psychotic
             disorder, or a current major depressive episode that includes psychotic features; or
             is currently psychotic.

          -  Patient is currently enrolled in a double blind investigational study; patients who
             have completed the double-blind D-21 study will be allowed to enter the Registry for
             Long Term Follow-up

          -  Other than those patients who were enrolled in the D-21 study, patient has previously
             received VNS therapy.

          -  Patient has a history of rapid cycling bipolar disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam K. Ashton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suburban Psychiatric Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY UMU at Syracuse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Zetin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darin D. Dougherty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Keepers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa M. Husain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leighton Y. Huey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Kimball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J. Holland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Atlantic University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Howland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute &amp; Clinic (WPIC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Rothschild, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig J Vine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric Recovery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Center for Behavioral Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence W Adler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Insights</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold Harsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syed Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dupage Mental Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keming Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Todd M. Antin, M.D., DFAPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pact Atlanta, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Basanti Basu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Century Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dwight Bearden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David L. Dunner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Anxiety and Depression</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azfar Malik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psych Care Consultants Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valdosta Psychiatric Associates LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick W. Reimherr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric &amp; Behavorial Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Zajecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric Medicine Associates, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Banov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest Behavioral Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Lehman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmasite Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Aaronson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheppard Pratt Health Systems, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaishree Narayanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Seal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Horacio Capote, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dent Neurologic Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Conway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lesem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Claghorn-Lesem Reserach Clinic, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Martelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MG Martelli, MD, PC and Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ananda Pandurangi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Institute for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Edelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jamaica Hospital Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bulow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Bunker</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahendra Bhati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Warnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janak Mehtani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fair Oaks Psychiatric Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mounir Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Holt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur Holt, Private Practice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold McGrath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGarth Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony D'Agostino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexian Brothers Behavioral Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>3c Methodist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Burke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Coffey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Kwentus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ginsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University of Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnold Mech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Mech Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Simpson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alamo Superior Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Hospital</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark Zetin, MD - Private Practice</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fair Oaks Psychiatric Associates</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-1410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Atlantic University</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MG Martelli, MD, PC and Associates</name>
      <address>
        <city>Brunswick</city>
        <state>Georgia</state>
        <zip>31520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur Holt, Private Practice</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pact Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Behavioral Research Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valdosta Psychiatric Associates LLC</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGrath Clinic</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Behavioral Health Hospital</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupage Mental Health Services</name>
      <address>
        <city>Wheaton</city>
        <state>Illinois</state>
        <zip>60187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3c Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Clinical Research, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health Systems, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Insights</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Center for Behavioral Medicine</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Recovery</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psych Care Consultants Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Psychiatric Associates</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY UMU at Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University - Health Sciences</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Century Health</name>
      <address>
        <city>Findlay</city>
        <state>Ohio</state>
        <zip>45840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute &amp; Clinic (WPIC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8898</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claghorn-Lesem Reserach Clinic, Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mech Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Superior Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric &amp; Behavioral Solutions</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Anxiety and Depression</name>
      <address>
        <city>Mercer Island</city>
        <state>Washington</state>
        <zip>98040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005 Sep 1;58(5):355-63.</citation>
    <PMID>16139581</PMID>
  </reference>
  <reference>
    <citation>Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 1;58(5):347-54.</citation>
    <PMID>16139580</PMID>
  </reference>
  <reference>
    <citation>George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005 Sep 1;58(5):364-73.</citation>
    <PMID>16139582</PMID>
  </reference>
  <reference>
    <citation>Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Müller-Siecheneder F, Audenaert K, van den Abbeele D, Matthews K, Christmas D, Eljamel S, Heuser I. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010 Jun;30(3):273-81. doi: 10.1097/JCP.0b013e3181db8831.</citation>
    <PMID>20473062</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2015</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Treatment-resistant Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The TRD Registry was to enroll over a maximum period of 6 years &amp; patients were to be followed for at least 60 months. All sites were to first recruit patients who had agreed to have adjunctive VNS Therapy. Sites were also asked to enroll patients with TRD who would not be implanted with VNS Therapy and would act as a concurrent control group.</recruitment_details>
      <pre_assignment_details>A total of 878 subjects were screened in the TRD Registry Study. Thirty-seven were not eligible and 46 were eligible but not treated for various reasons. This left a total of 795 patients in the Safety Population (SP).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VNS Therapy</title>
          <description>Disposition of study patients from baseline to the end of the study. The VNS Therapy arm, was comprised of D-23 Original patients (Patients that entered the TRD Registry without previous VNS Therapy treatment and selected the VNS Therapy study arm) and D-21 Rollover patients (Patients that entered the TRD Registry, having previously participated in the D-21 study-NCT00305565 and still being treated with VNS Therapy).</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual (TAU)</title>
          <description>Disposition of study patients from baseline to the end of the study. The TAU arm were subjects that entered the TRD Registry without previous VNS Therapy treatment and selected the TAU study arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
                <participants group_id="P2" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>VNS Therapy D-23 Original</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>VNS Therapy D-21 (NCT00305565) Rollovers</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Meet (I/E)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (i.e. lost to f/u, site closure)</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 878 subjects were screened. Thirty-seven were not eligible and 46 were eligible but not treated for various reasons. This left a total of 795 patients in the Safety Population (SP). The total number of patients in each group may be lower than SP if there was missing D-21 assessment data, as D-21 baseline data was not identical to D-23.</population>
      <group_list>
        <group group_id="B1">
          <title>VNS Therapy D-23 Original</title>
          <description>Subjects that entered the TRD Registry without previous VNS Therapy treatment and selected the VNS Therapy study arm.</description>
        </group>
        <group group_id="B2">
          <title>VNS Therapy D-21 Rollover</title>
          <description>Subjects that entered the TRD Registry, having previously participated in the D-21 study and still being treated with VNS Therapy treatment were included within the VNS Therapy group. Based on the duration from initial implant to enrollment date, the D-21 rollover patients entered at the appropriate D-23 follow-up interval (i.e., patient enrolls at 24 months post implant for their first D-23 follow up visit. This 24 month visit corresponds to the 24 month follow up in the TRD Registry). Starting with the first TRD Registry visit, the D-21 long-term patients were to follow the same data collection schedule as other Original VNS and TAU Registry patients.</description>
        </group>
        <group group_id="B3">
          <title>Treatment as Usual (TAU)</title>
          <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy. Subjects that entered the TRD Registry without previous VNS Therapy treatment and selected the TAU study arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="335"/>
            <count group_id="B2" value="159"/>
            <count group_id="B3" value="301"/>
            <count group_id="B4" value="795"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age at Baseline (n=335, n=159, n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="10.41"/>
                    <measurement group_id="B2" value="48.9" spread="9.51"/>
                    <measurement group_id="B3" value="49.9" spread="11.07"/>
                    <measurement group_id="B4" value="49.3" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Initial Onset of Depression(n=334,n=159,n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="12.13"/>
                    <measurement group_id="B2" value="21.1" spread="11.11"/>
                    <measurement group_id="B3" value="21.1" spread="11.40"/>
                    <measurement group_id="B4" value="21.0" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age-Initial Dx. of Depression(n=334,n=159,n=301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="10.95"/>
                    <measurement group_id="B2" value="28.6" spread="10.50"/>
                    <measurement group_id="B3" value="29.5" spread="11.89"/>
                    <measurement group_id="B4" value="29.1" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnic Orgin of participants in the study</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="274"/>
                    <measurement group_id="B4" value="752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Episodes of Depression Diagnosed (n=335, n=0, n=301)</title>
          <units>Lifetime Episodes of Depression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="24.14"/>
                    <measurement group_id="B2" value="NA">This Variable was captured as categorical variable as part of D-21 study</measurement>
                    <measurement group_id="B3" value="12.0" spread="23.86"/>
                    <measurement group_id="B4" value="13.5" spread="24.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Failed Treatments (n=335, n=159, n=301)</title>
          <units>Number of Failed Treatments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="3.05"/>
                    <measurement group_id="B2" value="8.6" spread="3.74"/>
                    <measurement group_id="B3" value="7.3" spread="2.92"/>
                    <measurement group_id="B4" value="7.9" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Suicide Attempts in Lifetime (n=335, n=159, n=301)</title>
          <units>Number of Suicide Attempts in a Lifetime</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="4.38"/>
                    <measurement group_id="B2" value="1.2" spread="2.95"/>
                    <measurement group_id="B3" value="1.2" spread="2.41"/>
                    <measurement group_id="B4" value="1.6" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis Disorder (Major Depressive Disorder (MDD) or Bipolar Disorder (BPD)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>MDD, Recurrent, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Recurrent, Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Single Episode, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Single Episode, Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD I, MRE Depressed, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD I, MRE Depressed,Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD II, MRE Depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)% Responders (&gt;/= 50% Improvement From Baseline)</title>
        <description>Response Rate was computed and summarized as the proportion of patients that achieved ≥ 50% reduction from baseline in MADRS total score at each post-baseline visit. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen. A patient was considered a “Responder” (Yes = 1) if achieved ≥ 50% reduction from baseline in MADRS total score at visit month assessment post-baseline. A “Non-Responder” (No = 0) was any patient who did not achieve ≥ 50% reduction from baseline in MADRS score at visit month assessment post-baseline.
Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>MADRS % Responders (Percentage of Responders)</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual (TAU)</title>
            <description>MADRS % Responders (Percentage of Responders)</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)% Responders (&gt;/= 50% Improvement From Baseline)</title>
          <description>Response Rate was computed and summarized as the proportion of patients that achieved ≥ 50% reduction from baseline in MADRS total score at each post-baseline visit. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen. A patient was considered a “Responder” (Yes = 1) if achieved ≥ 50% reduction from baseline in MADRS total score at visit month assessment post-baseline. A “Non-Responder” (No = 0) was any patient who did not achieve ≥ 50% reduction from baseline in MADRS score at visit month assessment post-baseline.
Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
          <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-Month (n=454, n=249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month (n=432, n=224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-Month (n=408, n=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month (n=403, n=194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-Month (n=223, n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month (n=233, n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-Month (n=224, n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-Month (n=245, n=133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42-Month (n=245, n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48-Month (n=246, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54-Month (n=222, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-Month (n=250, n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of responders across groups is the same. Alternate Hypothesis: Percentage of responders across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>38.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.3</ci_lower_limit>
            <ci_upper_limit>39.9</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on MADRS responders (binary variable with 1=yes, 0=no) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of responders across groups is the same. Alternate Hypothesis: Percentage of responders across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.2</ci_lower_limit>
            <ci_upper_limit>19.0</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on MADRS responders (binary variable with 1=yes, 0=no) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of responders across groups is the same. Alternate Hypothesis: Percentage of responders across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Until Recurrence (TUR) for Patients That Achieved Remission, Based on Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>Recurrence based on MADRS is defined as first time attained MADRS total score ≥ 20 after achieving remission. Remission is a binary outcome response variable (Yes/No in-remission) defined as MADRS total score &lt;/= 9 at visit month assessment post-baseline. Duration of remission Computed as recorded date of the first recurrence/relapse (MADRS score &gt;/= 20) minus the recorded date of first achieved remission (MADRS score &lt;/=9). Only a subpopulation that achieved remission will be included in the summary.
Time-to-event analyses were summarized using Kaplan-Meier curves. Patients who did not achieve recurrence at the end of the study were censored on the last visit date recorded. Additionally, patients who discontinued early were censored on last date of contact. Censored observations and confidence intervals for the estimated median times were calculated.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>Time until recurrence based on the MADRS</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual (TAU)</title>
            <description>Time until recurrence based on the MADRS</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Recurrence (TUR) for Patients That Achieved Remission, Based on Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>Recurrence based on MADRS is defined as first time attained MADRS total score ≥ 20 after achieving remission. Remission is a binary outcome response variable (Yes/No in-remission) defined as MADRS total score &lt;/= 9 at visit month assessment post-baseline. Duration of remission Computed as recorded date of the first recurrence/relapse (MADRS score &gt;/= 20) minus the recorded date of first achieved remission (MADRS score &lt;/=9). Only a subpopulation that achieved remission will be included in the summary.
Time-to-event analyses were summarized using Kaplan-Meier curves. Patients who did not achieve recurrence at the end of the study were censored on the last visit date recorded. Additionally, patients who discontinued early were censored on last date of contact. Censored observations and confidence intervals for the estimated median times were calculated.</description>
          <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Censored Patients</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Quartile (25%);Time (Mo.) Until Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O2" value="9" lower_limit="6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaplan-Meier Median;Time (Mo.) Until Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="26">Unable to compute based on Kaplan Meier Calculation due to too few events</measurement>
                    <measurement group_id="O2" value="19" lower_limit="10">Unable to compute based on Kaplan Meier Calculation due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1015</p_value>
            <p_value_desc>Comparison for Kaplan Meier Median Time until recurrence</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Null hypothesis: median TUR between 2 groups is not different. Alternate hypothesis: median TUR between 2 groups is different.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)% Remitters (MADRS Total Score ≤9 at Visit Month Assessment Post-Baseline)</title>
        <description>Remission is a binary outcome response variable (Yes/No Inremission) defined as MADRS total score &lt; 9 at visit month assessment post-baseline. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen and in general it is accepted that a score between 0-6 is indicative of a normal/symptom-free individual; 7-19 is indicative of a patient with mild depression; 20-34 is indicative of a patient with moderate depression; and &gt;34 is indicative of a patient with severe depression. Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>MADRS % Remitters (Percentage of Subjects in Remission)</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual (TAU)</title>
            <description>MADRS % Remitters (Percentage of Subjects in Remission)</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)% Remitters (MADRS Total Score ≤9 at Visit Month Assessment Post-Baseline)</title>
          <description>Remission is a binary outcome response variable (Yes/No Inremission) defined as MADRS total score &lt; 9 at visit month assessment post-baseline. The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The lower a score the less symptom severity is seen and in general it is accepted that a score between 0-6 is indicative of a normal/symptom-free individual; 7-19 is indicative of a patient with mild depression; 20-34 is indicative of a patient with moderate depression; and &gt;34 is indicative of a patient with severe depression. Total number of patients in each group may be lower than ITT in a case of missing assessment data.</description>
          <population>Intent-To-Treat (ITT) Population: VNS Therapy Population (n=489 (D-23=330 + D-21=159)) + (n= 276) TAU population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-Month (n=454, n=249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month (n=432, n=224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-Month (n=408, n=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month (n=403, n=194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-Month (n=223, n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month (n=233, n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-Month (n=224, n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-Month (n=245, n=133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42-Month (n=245, n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48-Month (n=246, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54-Month (n=222, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-Month (n=250, n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of remitters across groups is the same. Alternate Hypothesis: Percentage of remitters across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>19.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.4</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on MADRS remitters (binary variable with 1=yes, 0=no) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of remitters across groups is the same. Alternate Hypothesis: Percentage of remitters across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.9</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on MADRS remitters (binary variable with 1=yes, 0=no) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Percentage of responders across groups is the same. Alternate Hypothesis: Percentage of responders across groups is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality and Suicidality in Safety Population (Total Number of Deaths)</title>
        <description>The number of deaths on the study were collected from the baseline visit.</description>
        <time_frame>3-Month (baseline or implantation) Through 60-Month (Post Baseline)</time_frame>
        <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Suicidality in Safety Population (Total Number of Deaths)</title>
          <description>The number of deaths on the study were collected from the baseline visit.</description>
          <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
          <units>Number of Deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality and Suicidality in Safety Population (Total Patient Years Exposed)</title>
        <description>Treatment exposure time in years for all patients for all treatment groups were calculated in 1000 person year measure.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Suicidality in Safety Population (Total Patient Years Exposed)</title>
          <description>Treatment exposure time in years for all patients for all treatment groups were calculated in 1000 person year measure.</description>
          <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
          <units>Exposure Per 1000 Patient Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985.083"/>
                    <measurement group_id="O2" value="926.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality and Suicidality in Safety Population (All-Cause Mortality/1000 Person Years)</title>
        <description>All cause mortality is defined as the number of deaths per calculated 1000 person years.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Suicidality in Safety Population (All-Cause Mortality/1000 Person Years)</title>
          <description>All cause mortality is defined as the number of deaths per calculated 1000 person years.</description>
          <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
          <units>Deaths Per 1000 Person Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53"/>
                    <measurement group_id="O2" value="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality and Suicidality in Safety Population (Number of Suicides)</title>
        <description>The number suicides on the study were collected from the baseline visit.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Suicidality in Safety Population (Number of Suicides)</title>
          <description>The number suicides on the study were collected from the baseline visit.</description>
          <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
          <units>Number of Suicides</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mortality and Suicidality in Safety Population (Suicides/1000 Person Years)</title>
        <description>The number of suicides per calculated 1000 person years.</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>VNS Patients - Treatment-resistant depression patients treated with VNS Therapy</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual (TAU)</title>
            <description>Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality and Suicidality in Safety Population (Suicides/1000 Person Years)</title>
          <description>The number of suicides per calculated 1000 person years.</description>
          <population>Safety Population (SP): VNS Therapy Population (n=494 (D-23=335 + D-21=159)) + (n= 301) TAU population</population>
          <units>Number of Suicides Per 1000 Person Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                    <measurement group_id="O2" value="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Baseline MADRS Item 10 Suicidal Ideation</title>
        <description>This assessment was completed telephonically by a third party rater (Central Rater Group). The rating was based on a clinical interview moving from broadly phrased questions about symptoms to more detailed ones, which allowed a precise rating of severity. The rater decided whether the rating lied on the defined scale steps (0, 2, 4, 6) or between them (1, 3, 5) and then checked the appropriate selection on the MADRS Item 10 Suicidal Thoughts (Ideation).
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
        <time_frame>1 Week Pre-Baseline</time_frame>
        <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 2 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>VNS Therapy and Treatment as Usual (TAU)</description>
          </group>
        </group_list>
        <measure>
          <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Baseline MADRS Item 10 Suicidal Ideation</title>
          <description>This assessment was completed telephonically by a third party rater (Central Rater Group). The rating was based on a clinical interview moving from broadly phrased questions about symptoms to more detailed ones, which allowed a precise rating of severity. The rater decided whether the rating lied on the defined scale steps (0, 2, 4, 6) or between them (1, 3, 5) and then checked the appropriate selection on the MADRS Item 10 Suicidal Thoughts (Ideation).
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
          <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 2 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Enjoys Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weary of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Probably Better Off Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Explicit Plans for Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The statistical modeling of predictors of suicide attempts and suicidal ideations considered 15 variables, defined in the protocol a priori to determine which ones were predictive of suicide attempts and suicidal ideations. Four variables representing the baseline disease and patient factors were considered predictors of suicidality. This outcome measure presents the underlying data collected and the corresponding correlation coefficient for one of the 4 variables identified.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Null hypothesis: There is a correlation between MADRS follow-up suicidal thoughts and baseline suicidal thoughts.
Alternate hypothesis: There is no correlation between MADRS follow-up suicidal thoughts and baseline suicidal thoughts.</p_value_desc>
            <method>Pearson Correlation Coefficients</method>
            <param_type>Pearson Correlation Coefficients</param_type>
            <param_value>.34997</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Change From Baseline by Visit Month</title>
        <description>The Q-LES-Q-SF is a self-report scale to assess the degree of enjoyment and satisfaction experienced by the patient during the past week. There are 2 forms of this instrument: the short form and the long form. The short form employs the 14 general activities included in the long form, as well as 2 global items. Five-point item scores (1 to 5) are aggregated, with higher scores indicative of greater enjoyment or satisfaction in each domain. The scoring of the Q-LESQ-SF involves summing only the first 14 items to yield a raw total score. The last 2 items are not included in the total score but stand alone. The raw total score ranges from 14 (worst score) to 70 (best score). Higher Q-LES-QSF score indicates more enjoyment and satisfaction (Endicott, Nee et al. 1993).</description>
        <time_frame>3-Month Through 60-Month (Post Baseline)</time_frame>
        <population>ITT Population minus D-21 Subjects: VNS Therapy Population (D-23=330) + (n= 276) TAU population. The total number of patients in each group is lower than ITT due to missing assessment data, for which a large portion is that of D-21 subjects. The Q-LES-Q-SF was not collected in the D-21 Study.</population>
        <group_list>
          <group group_id="O1">
            <title>VNS Therapy</title>
            <description>Change from Baseline Score</description>
          </group>
          <group group_id="O2">
            <title>Treatment As Usual (TAU)</title>
            <description>Change from Baseline Score</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Change From Baseline by Visit Month</title>
          <description>The Q-LES-Q-SF is a self-report scale to assess the degree of enjoyment and satisfaction experienced by the patient during the past week. There are 2 forms of this instrument: the short form and the long form. The short form employs the 14 general activities included in the long form, as well as 2 global items. Five-point item scores (1 to 5) are aggregated, with higher scores indicative of greater enjoyment or satisfaction in each domain. The scoring of the Q-LESQ-SF involves summing only the first 14 items to yield a raw total score. The last 2 items are not included in the total score but stand alone. The raw total score ranges from 14 (worst score) to 70 (best score). Higher Q-LES-QSF score indicates more enjoyment and satisfaction (Endicott, Nee et al. 1993).</description>
          <population>ITT Population minus D-21 Subjects: VNS Therapy Population (D-23=330) + (n= 276) TAU population. The total number of patients in each group is lower than ITT due to missing assessment data, for which a large portion is that of D-21 subjects. The Q-LES-Q-SF was not collected in the D-21 Study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months (n=322, n=261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="16.20"/>
                    <measurement group_id="O2" value="1.38" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=298, n=239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" spread="15.66"/>
                    <measurement group_id="O2" value="4.36" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months (n=270, n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="16.74"/>
                    <measurement group_id="O2" value="3.97" spread="17.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months (n=266, n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" spread="18.36"/>
                    <measurement group_id="O2" value="5.49" spread="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months (n=264, n=179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="18.29"/>
                    <measurement group_id="O2" value="3.88" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=240, n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.15" spread="18.13"/>
                    <measurement group_id="O2" value="7.50" spread="16.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Months (n=223, n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.06" spread="18.63"/>
                    <measurement group_id="O2" value="8.13" spread="16.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=219, n=149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.59" spread="18.43"/>
                    <measurement group_id="O2" value="8.34" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 Months (n=196, n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" spread="17.46"/>
                    <measurement group_id="O2" value="8.55" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=179, n=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.70" spread="19.02"/>
                    <measurement group_id="O2" value="9.88" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 Months (n=156, n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.44" spread="18.63"/>
                    <measurement group_id="O2" value="10.49" spread="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=173, n=136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.20" spread="17.59"/>
                    <measurement group_id="O2" value="10.11" spread="17.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>3 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>6 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0068</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>9 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0008</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0003</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>18 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0059</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>30 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0028</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0002</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>42 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0051</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0363</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>54 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0048</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>60 Month Time point</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0009</p_value>
            <p_value_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</p_value_desc>
            <method>F-Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>12.1009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.8979</ci_lower_limit>
            <ci_upper_limit>13.3039</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on Q-LES-Q change from baseline score (continuous var) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>MMRM Least Squares Mean</param_type>
            <param_value>7.5964</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.1327</ci_lower_limit>
            <ci_upper_limit>9.0602</ci_upper_limit>
            <estimate_desc>Mixed Model Repeated Measure analysis on Q-LES-Q change from baseline score (continuous var) as the response variable in the model. The covariates are treatment, visit and propensity quintile. This analysis of covariance produced least square means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Difference between change from baseline value of two treatment groups equals zero.
Alternate Hypothesis: Difference between change from baseline value of two treatment groups is not equal to zero.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Medical Threat to Life of Most Recent Suicidal Gesture</title>
        <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's medical threat to life of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
        <time_frame>Baseline</time_frame>
        <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 159 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>VNS Therapy and Treatment as Usual (TAU)</description>
          </group>
        </group_list>
        <measure>
          <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Medical Threat to Life of Most Recent Suicidal Gesture</title>
          <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's medical threat to life of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
          <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 159 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient Never Made an Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Information or Not Sure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Danger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The statistical modeling of predictors of suicide attempts and suicidal ideations considered 15 variables, defined in the protocol a priori to determine which ones were predictive of suicide attempts and suicidal ideations. Four variables representing the baseline disease and patient factors were considered predictors of suicidality. This outcome measure presents the underlying data collected and the corresponding correlation coefficient for one of the 4 variables identified.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Null hypothesis: There is a correlation between MADRS follow-up suicidal thoughts and baseline medical threat to life.
Alternate hypothesis: There is no correlation between MADRS follow-up suicidal thoughts and baseline medical threat to life.</p_value_desc>
            <method>Pearson Correlation Coefficients</method>
            <param_type>Pearson Correlation Coefficients</param_type>
            <param_value>.14837</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Intent of Most Recent Suicidal Gesture</title>
        <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's intent of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
        <time_frame>Baseline</time_frame>
        <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 159 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>VNS Therapy and Treatment as Usual (TAU)</description>
          </group>
        </group_list>
        <measure>
          <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Intent of Most Recent Suicidal Gesture</title>
          <description>This assessment was completed by the physician at the baseline visit in a clinical interview. The physician decided which category (as shown in outcome measure data table) best characterized the patient's intent of their most recent suicidal gesture or attempt.
Total number of patients analyzed may be lower than ITT in a case of missing assessment data.</description>
          <population>D-23 Original + TAU [(n= 330) + (n= 276)] minus 159 missing assessment data. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient Never Made an Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Information or Not Sure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obviously no Intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Sure or Only Minimal Intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite But Very Ambivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The statistical modeling of predictors of suicide attempts and suicidal ideations considered 15 variables, defined in the protocol a priori to determine which ones were predictive of suicide attempts and suicidal ideations. Four variables representing the baseline disease and patient factors were considered predictors of suicidality. This outcome measure presents the underlying data collected and the corresponding correlation coefficient for one of the 4 variables identified.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Null hypothesis: There is a correlation between MADRS f/u suicidal thoughts and baseline intent of suicidal gesture.
Alternate hypothesis: There is no correlation between MADRS f/u suicidal thoughts and baseline intent of suicidal gesture.</p_value_desc>
            <method>Pearson Correlation Coefficients</method>
            <param_type>Pearson Correlation Coefficients</param_type>
            <param_value>.14819</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Primary Diagnosis of MDE</title>
        <description>This assessment was completed by the physician at the screening visit. The physician decided which DSM-IV Diagnosis (as shown in outcome measure data table) best characterized the patient's primary diagnosis of MDE.</description>
        <time_frame>Screening</time_frame>
        <population>D-23 Original + TAU [(n= 330) + (n= 276)]. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT Population</title>
            <description>VNS Therapy and Treatment as Usual (TAU)</description>
          </group>
        </group_list>
        <measure>
          <title>Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Primary Diagnosis of MDE</title>
          <description>This assessment was completed by the physician at the screening visit. The physician decided which DSM-IV Diagnosis (as shown in outcome measure data table) best characterized the patient's primary diagnosis of MDE.</description>
          <population>D-23 Original + TAU [(n= 330) + (n= 276)]. These risk factors assessed at baseline and pre-baseline were not collected with respect to treatment, therefore this information is not presented by treatment arm.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MDD, Recurrent, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Recurrent, Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Single Episode, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDD, Single Episode, Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD I, MRE Depressed, Moderate Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD I, MRE Depressed,Severe w/o Psychotic Features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD II, MRE Depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The statistical modeling of predictors of suicide attempts and suicidal ideations considered 15 variables, defined in the protocol a priori to determine which ones were predictive of suicide attempts and suicidal ideations. Four variables representing the baseline disease and patient factors were considered predictors of suicidality. This outcome measure presents the underlying data collected and the corresponding correlation coefficient for one of the 4 variables identified.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0012</p_value>
            <p_value_desc>Null hypothesis: There is a correlation between MADRS follow-up suicidal thoughts and baseline primary diagnosis of MDE.
Alternate hypothesis: There is no correlation between MADRS follow-up suicidal thoughts and baseline primary diagnosis of MDE.</p_value_desc>
            <method>Pearson Correlation Coefficients</method>
            <param_type>Pearson Correlation Coefficients</param_type>
            <param_value>.04625</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>N/A (Adverse event information was not collected as part of the TRD Registry Protocol)</time_frame>
      <desc>Physicians were instructed to notify Cyberonics' Clinical Technical Support (CTS) department of all Medical Devices Reporting (MDR) events that occurred in TRD Registry participants receiving VNS Therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Events</title>
          <description>N/A (not collected)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Bunker, PharmD, Sr. Director, Global Medical Affairs</name_or_title>
      <organization>Cyberonics, Inc</organization>
      <phone>281-228-7223</phone>
      <email>mark.bunker@cyberonics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

